West Pharmaceutical Services, a global manufacturer of components and systems for injectable drug delivery, has signed an agreement with Amgen, an independent biotech based in Thousand Oaks, Calif., to evaluate Daikyo Crystal Zenith technologies for drug containment.
The Crystal Zenith technologies were developed over many years by West's partner, Daikyo Seiko, and are based on a polymeric container, utilizing elastomeric components with Flurotec barrier film, and provided in a sterile, validated, ready-to-fill format.
"Biopharmaceutical therapeutic products require a drug container that enables safe, effective and reliable containment," said Donald E. Morel, Jr., Ph.D., West's chairman and CEO. "We are delighted to formalize our plan to work with Amgen for evaluating the use of Daikyo Crystal Zenith in commercializing Amgen's therapeutics. We value this long-standing relationship and look forward to helping Amgen to meet its objective of advancing science and biotechnology to serve patients."
No further details of the agreement were disclosed.